Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMC125 (Etravirine) in PI-naïve, NNRTI-resistant HIV-1
NCT00225303Phase 2Completed
- Sponsor
- Tibotec
- Start
- Mar 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of etravirine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Tibotec. Primary endpoint: Proportion of subjects with plasma HIV-1 RNA levels < 50 copies/mL at 24 weeks. Started Mar 2005; status: completed.
02
Drugs
etravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00225303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00225303.